331 |
Future Technologies from Cordis |
David E. Kandzari |
Oct. 05. 07 |
330 |
Long-Term Evaluation of DES vs. BMS; 10-Year Experience from Single Center Registry |
Seung-Jung Park |
Oct. 05. 07 |
329 |
Cypher in Complex Lesion |
Alexandre Abizaid |
Oct. 05. 07 |
328 |
Addressing the Controversy of Late DES Thrombosis |
Martin Bert Leon |
Oct. 05. 07 |
327 |
TAXUS Clinical Result Updates & Future Pipeline |
Joerg Koglin |
Oct. 05. 07 |
326 |
Bifurcations and Left Main with TAXUS |
Thierry Lefevre |
Oct. 05. 07 |
325 |
Better Diabetic Performance in TAXUS |
Antonio Colombo |
Oct. 05. 07 |
324 |
The Science Behind Xience V |
Jacques J. Koolen |
Sep. 28. 07 |
323 |
SPIRIT III (US Pivotal Study Results for Xience V Everolimus Eluting Coronary Stent) |
Gregg W. Stone |
Sep. 28. 07 |
322 |
DES Safety Concerns: Impact on Clinical Practice |
Martin Bert Leon |
Sep. 28. 07 |